Press Releases

Recent Press Releases

06/05/2011

Plexxikon Reports Positive Data from Phase 3 and Phase 2 Trials of Vemurafenib (PLX4032)

06/02/2011

Plexxikon Announces Combination Trials for Vemurafenib in Melanoma

05/18/2011

Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting

05/10/2011

New Drug Applications Submitted for Vemurafenib Market Approval in Melanoma

04/04/2011

Daiichi Sankyo Completes Plexxikon Acquisition

03/08/2011

Plexxikon Initiates Phase 2 Clinical Trial in Hodgkin Lymphoma with PLX3397

02/28/2011

Daiichi Sankyo To Acquire Plexxikon

01/27/2011

Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622

01/18/2011

Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial

01/06/2011

Plexxikon Signs Agreement with Genentech to Co-Promote PLX4032 in the US

Archived Press Releases